Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial
Sunil Patel, David R. Lally, Jason Hsu, Charles C. Wykoff, David Eichenbaum, Jeffrey S. Heier, Glenn J. Jaffe, Keith Westby, Dhaval Desai, Liansheng Zhu, Arshad M. Khanani
Abstract
In the sub-section “Safety analysis,” the percentage 0.6% in the sentence “There was 1 ocular SAE (0.6%; optic ischemic neuropathy) with ACP 2 mg and 1 (1.2%; retinal detachment) with ACP 4 mg” was corrected to 1.5%. In the same section, the percentage in the sentence “One eye (0.6%) in the 2 mg ACP cohort developed intraocular inflammation (IOI) during the study, a case of vitritis, at month 7 without any anterior chamber inflammation” was again corrected to 1.5%. Furthermore, the sentence “The TEAEs were cystoid macular degeneration (4 mg, 1.2%), ischemic optic neuropathy (2 mg, 2.4%), and retinal detachment (4 mg, 1.2%).” was corrected to read “The TEAEs were cystoid macular degeneration (4 mg, 1.2%), ischemic optic neuropathy (2 mg, 1.5%), and retinal detachment (4 mg, 1.2%)”. Finally, the footnote of Supplementary Table 4 was corrected from “Based on a mixed-effects model for repeated measures assuming a piecewise linear trend in time with knots at Month 6, Month 12, and Month 18” to “Based on a mixed-effects model for repeated measures assuming a piecewise linear trend in between times: 0 to Month 6, Month 6 to Month 12, and Month 12 to Month 18”. The original article has been corrected.